Abstract:Transarterial chemoembolization (TACE) is an image-guided locoregional therapy used for the treatment of patients with primary hepatocellular carcinoma (HCC). However, conventional TACE formulations such as epirubicin-lipiodol emulsion are rapidly dissociated due to the instability of the emulsion, result-ing in insufficient local drug concentrations in the target tumor. To overcome these limitations, we used biodegradable Idarubicin loaded microspheres (BILMs), which were prepared from gelatin and car-rageenan and could be loaded with Idarubicin (IDA-MS). The morphology and the ability to load and release IDA of BILMs were characterized in vitro. We evaluated tumor changes and side effects after TACE treatment with IDA-MS in VX2 rabbit and C57BL/6 mice HCC models. In addition, the effect of IDA-MS on the tumor immune microenvironment of HCC tumors was elucidated via mass spectrometry and im-munohistochemistry. Result showed that IDA-MS was developed as a new TACE formulation to overcome the poor delivery of drugs due to rapid elimination of the anticancer drug into the systemic circulation. We demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in significant tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment.Conventional transarterial chemoembolization (TACE) formulations are rapidly dissociated due to the in-stability of the emulsion, resulting in insufficient local drug concentrations in hepatocellular carcinoma (HCC). To overcome these limitations, we used biodegradable microspheres called BILMs, which could be loaded with Idarubicin (IDA-MS). We demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in significant tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment.(c) 2022 The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Gelation Embolism Agents Suppress Clinical TACE-incited Pro-Metastatic Microenvironment Against Hepatocellular Carcinoma Progression.

Superstable Homogeneous Iodinated Formulation Technology: Revolutionizing Transcatheter Arterial Chemoembolization

Procoagulant CaCO3-embedded embolic microspheres can potentiate transcatheter arterial embolization of hepatocellular carcinoma

Monodisperse CaCO3-loaded Gelatin Microspheres for Reversing Lactic Acid-Induced Chemotherapy Resistance During TACE Treatment.

Idarubicin-loaded Degradable Hydrogel for TACE Therapy Enhances Anti-Tumor Immunity in Hepatocellular Carcinoma

A Study on Overcoming Post‐TACE Drug Resistance in HCC Based on Controllable Oxygen Release‐Magnetic Hyperthermia Therapy

HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma

Caco3-Encapuslated Microspheres For Enhanced Transhepatic Arterial Embolization Treatment Of Hepatocellular Carcinoma

Sustained Release Hypoxia-Activated Prodrug-Loaded BSA Nanoparticles Enhance Transarterial Chemoembolization Against Hepatocellular Carcinoma.

Temperature-sensitive nanogels combined with polyphosphate and cisplatin for the enhancement of tumor artery embolization by coagulation activation

Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models

Homogenous multifunctional microspheres induce ferroptosis to promote the anti-hepatocarcinoma effect of chemoembolization

CaCO 3 ‐Encapuslated Microspheres for Enhanced Transhepatic Arterial Embolization Treatment of Hepatocellular Carcinoma

Responsively Aggregatable Nanochelator-Mediated Antiangiogenesis to Enhance Interventional Therapies for Liver Cancer

Rhein‐based Pickering Emulsion for Hepatocellular Carcinoma: Shaping the Metabolic Signaling and Immunoactivation in Transarterial Chemoembolization

Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer

Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin

Idarubicin-loaded Biodegradable Microspheres Enhance Sensitivity to Anti-Pd1 Immunotherapy in Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.

Biodegradable Microembolics with Nanografted Polyanions Enable High-Efficiency Drug Loading and Sustained Deep-Tumor Drug Penetration for Locoregional Chemoembolization Treatment

A Lipiodol Pickering Emulsion Stabilized by Iron‐Doped Carbon Nanozymes for Liver Transarterial Chemoembolization

Boost Therapy of Hepatocellular Carcinoma by Amplifying Vicious Cycle Between Mitochondrial Oxidative Stress and Endoplasmic Reticulum Stress Via Biodegradable Ultrasmall Nanoparticles and Old Drug